Treatment Information

Back

Breast Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jun 2014

Description:

Patients:
This phase 2 study involved 22 previously treated, metastatic breast cancer with a median age of 51 years (range 38-70).

Treatment:
Patients were treated with the biologic therapy agent called ganetespib, which is an inhibitor of the Heat Shock Protein 90 (HSP90) that interferes with breast cancer cell growth.

Toxicities:
The most severe toxicities were of grade 3 and included abdominal pain, shortness of breath, and diarrhea.

Results:
The median overall survival was 10.6 months.

Support:
Some of the authors were employed by Synta Pharmaceuticals, Inc., makers of the study drug.

Correspondence: Dr. Shanu Modi; email: [email protected]



Back